secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0000950170-22-026333
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio presents preclinical data for sequencing method to measure gene editing outcomes in sickle cell
--------------------------------------------------------------------------------

- Preclinical data presented at ASH on single-cell RNA sequencing method to assess gene correction in reticulocytes.
- Method accurately differentiated AA, AS, and SS reticulocytes in proof-of-concept mixtures.
- Method will be used to measure gene editing outcomes in patients treated with nula-cel (GPH101) for sickle cell disease.
- Nula-cel is being evaluated in the CEDAR Phase 1/2 trial with Fast Track and Orphan Drug designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017022026333/0000950170-22-026333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017022026333/grph-20221211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer